EUDA Health Holdings Limited is classed by the SEC under Services-Health Services (industry code 8000). In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $7 million and a loss of $3 million (its filed statements).
Usage businessServices-Health Servicesfilings since 20217 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8000, Services-Health Services); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.5 out of ten, 7 of 9 metrics filed and 2 estimated: past 4.6 out of ten, present 2.9 out of ten, future 6.6 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 5.3 out of ten. 8 warning events since 2021; the latest 2024-04-30. 53rd percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 2.3 out of ten. +10.6% a year over 5 filed years; profitable in 1 of 6. 23rd percentile among 14 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 8.2 out of ten. CrossAssetData estimate 8.2/10, confidence 35 of 100 (one part). 82nd percentile among 14 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 4.1 out of ten. Leverage 348%: owes 348¢ per asset dollar. 41st percentile among 14 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 3.2 out of ten. bottom 32% of 14 in its family; net margin -40.7%. 32nd percentile among 14 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 0.5 out of ten. CrossAssetData estimate 0.5/10, confidence 35 of 100 (one part). 5th percentile among 13 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Room to expand (future): 3.3 out of ten. bottom 33% of 14 in its family for room to expand. 33rd percentile among 14 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 7.5 out of ten. top 25% of 14 in its family for growth drivers. 75th percentile among 14 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 7.6 out of ten. top 24% of 12 in its family for expectations against reality. 76th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-04-28 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2023-07-31 for the period ended 2023-03-31 (on EDGAR). Newest filing: Form 6-K, 2026-09-29. Filings on record since 2021. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Property Management Service Common Area Management 48%, Wellness Therapies Service 26%, Property Management Service Security Management 16%, Holistic Wellness Consumer Products 6%, Stem Cell Treatment Service 3%, Licensing Service of Bio Energy Cabin 1%. By geography: Singapore 71%, Malaysia 29%. As tagged in its annual report (Form 20-F, filed 2026-04-28).
Who runs it
Tay, Whye Shin (Chief Financial Officer); Huang, Bo (director); Lew, Chern Yong (director); Liew, Kwong Yeow (director). 4 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.